Breast Cancer Survivors May Benefit From Phone-Based Weight Loss Program 

Article

Data from a phase 3 study indicate that weight loss intervention with a telephone-based program appears to be effective across all subgroups of breast cancer survivors.

A weight loss intervention program available via the internet and telephone effectively helped with weight loss among patients with breast cancer who had obesity, according to findings from a phase 3 trial presented during a press briefing prior to the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

"Now that we have demonstrated that our intervention was successful in inducing weight loss, we will be able to determine whether losing weight after a breast cancer diagnosis improves outcomes in these women," according to an expert from Dana-Farber Cancer Institute.

"Now that we have demonstrated that our intervention was successful in inducing weight loss, we will be able to determine whether losing weight after a breast cancer diagnosis improves outcomes in these women," according to an expert from Dana-Farber Cancer Institute.

“Obesity is a poor prognostic factor in early breast cancer,” study author Jennifer Ligibel, MD, a medical oncologist at the Dana-Farber Cancer Institute in Boston, Massachusetts, said in a presentation of the results ahead of the meeting. “Women with obesity at the time of a breast cancer diagnosis have a higher risk of cancer recurrence, cancer-related mortality and overall mortality compared to women with a body mass index [BMI] in the normal range at the time of their breast cancer diagnosis.”

The phase 3 Breast Cancer Weight Loss Trial included 3,136 patients with stage I through III HR-positive, HER2-negative or triple-negative breast cancer who were diagnosed within 14 months from the start of the trial. To be eligible for the trial, they must have a BMI at or above 27 kg/m2—which is in the upper end of the overweight range, according to Ligibel.

Participants were randomly assigned to have health education plus 2 years of telephone-based weight loss (which included 42 calls from a health coach and supplemental workbook and tools) or health education alone. The phone-based weight loss program focused on patients lowering calories and increasing physical activity.

The main goal of the study was to see if there was a difference in invasive disease-free survival, with the key secondary end point being weight change.

Study findings showed that patients in the weight loss intervention group tended to lose more weight than those who just underwent the initial education. At the 6-month mark, those in the intervention group lost an average of 4.4 kg, while those in the control group gained an average of .2 kg. At 12 months, those in the intervention group had an average loss of 4.4 kg again, while the education-only group had an average weight gain of .9 kg.

“This equated to a 5.65% weight differential in the 2 arms, demonstrating significant weight loss which was also clinically significant given that a 3% weight loss is sufficient to improve diabetes and other chronic diseases,” Ligibel said.

When broken down by subgroup, the researchers found that menopausal status and race/ethnicity tended to affect the amount of weight lost. Specifically, post-menopausal women tended to experience a higher percentage of weight change than pre-menopausal women (6.39% vs 4.68%, respectively). Regarding race/ethnicity, African Americans lost an average of 3.74%, while Hispanic patients lost an average of 4.13%, and other ethnicities lost an average of 6.05%.

“However, across all of these subgroups, the weight loss intervention was highly successful in helping patients to achieve meaningful weight loss,” Ligibel mentioned.

Looking ahead, Ligibel said that the Breast Cancer Weight Loss Trial will continue to follow patients to determine if the weight loss has an impact on invasive disease-free survival and other breast cancer outcomes.

“Now that we have demonstrated that our intervention was successful in inducing weight loss, we will be able to determine whether losing weight after a breast cancer diagnosis improves outcomes in these women,” Ligibel said.

Reference

Ligibel J. Effect of a telephone-based weight loss intervention (WLI) on weight at 12-months in women with early breast cancer: Results from the Breast Cancer Weight Loss (BWEL) trial. Presented at: 2023 ASCO Annual Meeting. Abstract 12001.

Recent Videos
James Ninia, MD, discussed treatment options for patients with extensive-stage small cell lung cancer undergoing metastasis-directed radiotherapy.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Higher, durable rates of response to frontline therapy are needed to potentially improve long-term survival among patients with non–small cell lung cancer.
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.
Related Content